paroxetine

(redirected from Pexeva)
Also found in: Dictionary.
Related to Pexeva: Paxil

paroxetine

 [pah-rok´sĕ-tēn]
a selective serotonin reuptake inhibitor administered orally as the hydrochloride salt as an antidepressant and to treat obsessive-compulsive, panic, and social anxiety disorders.

paroxetine

/par·ox·e·tine/ (pah-rok´sĕ-tēn) a selective serotonin uptake inhibitor used as the hydrochloride salt to treat depression and obsessive-compulsive, panic, and social anxiety disorders.

paroxetine

(pă-rŏk′sĭ-tēn′)
n.
A drug of the SSRI class, C19H20FNO3, used in its hydrochloride form to treat depression, anxiety, and certain other disorders, including obsessive-compulsive disorder.

paroxetine

a selective serotonin reuptake inhibitor.
indications It is prescribed in the treatment of mental depression, obsessive-compulsive disorder, panic disorders, and anxiety disorders, including social anxiety and general anxiety. Unlabeled uses include treatment of impulse control disorders, premenstrual syndrome, and vasomotor symptoms of menopause.
contraindications It should not be given to patients taking monoamine oxidase inhibitors. Caution is advised in administering the drug to patients with a history of drug abuse, mania, seizures, suicidal tendencies, or kidney or liver disease.
adverse effects The side effects most often reported include decreased libido and ejaculatory disturbances, nausea, diarrhea, vomiting, constipation, abdominal pain, flatulence, changes in appetite, and muscle weakness. Paroxetine may also cause SIADH and/or hyponatremia and lead to or exacerbate coagulation disturbances because of impairment of platelet aggregation.

paroxetine

A SEROTONIN RE-UPTAKE INHIBITOR drug. A brand name is Seroxat.

paroxetine,

n brand name: Paxil;
drug class: antidepressant;
action: selectively inhibits the uptake of serotonin in the brain;
use: depression.
References in periodicals archive ?
0 million accrued liability (the "Pexeva Reversal") related to a future Pexeva contingent sales milestone no longer expected to be achieved.
2 million in the 2007 second quarter due to the addition of the Noven Therapeutics marketing and sales infrastructure supporting Pexeva, Lithobid and Stavzor (approved by the FDA in July 2008).
3 million in Pexeva and Lithobid product sales, as well as increased license and contract revenues, primarily due to amortization of deferred revenue from additional Daytrana sales milestones received in 2007.
Synthon Pharmaceuticals has developed Pexeva, a generic version priced much lower than GSK's drug and 20% less than two other generic versions of Paxil.
Under the terms of the agreement, Ventiv will initially provide 8 district managers and 100 full-time sales representatives (70 primary care and 30 specialty reps) to drive sales and market share of Pexeva among targeted psychiatrists and primary care physicians.
Launching both Pexeva and Synthon simultaneously in the United States requires the best and most experienced team.